Pulmonary Regurgitation- Is the Future Percutaneous or Surgical?

Morgan, Gareth J.

doi:10.3389/fped.2018.00184

Cited by 7 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical replacement of the pulmonary valve remains the first-line procedure for valve replacement despite the rapid progress made in transcatheter pulmonary valve implantation in the right ventricular outflow tract [1]. This is highlighted by an implantation rate of only 58% of patients presenting for such a procedure in a recent retrospective multicentre trial in the USA including 3% of patients requiring urgent surgery for stent embolization [2].…”

Section: Introductionmentioning

confidence: 99%

A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data†

Boethig

Horke

Hazekamp

et al. 2019

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

OBJECTIVES Decellularized pulmonary homografts (DPH) have shown excellent results for pulmonary valve replacement. However, controlled multicentre studies are lacking to date. METHODS Prospective European multicentre trial evaluating DPH for pulmonary valve replacement. Matched comparison of DPH to bovine jugular vein (BJV) conduits and cryopreserved homografts (CH) considering patient age, type of heart defect and previous procedures. RESULTS In total, 121 patients (59 female) were prospectively enrolled (August 2014–December 2016), age 21.3 ± 14.4 years, DPH diameter 24.4 ± 2.8 mm. No adverse events occurred with respect to surgical handling; there were 2 early deaths (30 + 59 years) due to myocardial failure after multi-valve procedures and no late mortality (1.7% mortality). After a mean follow-up of 2.2 ± 0.6 years, the primary efficacy end points mean peak gradient (16.1 ± 12.1 mmHg) and regurgitation (mean 0.25 ± 0.48, grade 0–3) were excellent. One reoperation was required for recurrent subvalvular stenosis caused by a pericardial patch and 1 balloon dilatation was performed on a previously stented LPA. 100% follow-up for DPH patients operated before or outside the trial (n = 114) included in the ESPOIR Registry, age 16.6 ± 10.4 years, diameter 24.1 ± 4.2 mm, follow-up 5.1 ± 3.0 years. The combined DPH cohort, n = 235, comprising both Trial and Registry data showed significantly better freedom from explantation (DPH 96.7 ± 2.1%, CH 84.4 ± 3.2%, P = 0.029 and BJV 82.7 ± 3.2%, P = 0.012) and less structural valve degeneration at 10 years when matched to CH, n = 235 and BJV, n = 235 (DPH 61.4 ± 6.6%, CH 39.9 ± 4.4%, n.s., BJV 47.5 ± 4.5%, P = 0.029). CONCLUSIONS: Initial results of the prospective multicentre ESPOIR Trial showed DPH to be safe and efficient. Current DPH results including Registry data were superior to BJV and CH. Trial registration clinicaltrials.gov identifier: NCT 02035540.

show abstract

Section: Introductionmentioning

confidence: 99%

A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data†

Boethig

Horke

Hazekamp

et al. 2019

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…Early experience revealed a significant tendency to develop clinically significant frame fractures without multiple bolstering pre‐stents. Although a definitive study is still not available, circumstantial and retrospective cohort data suggests that the incidence of infective endocarditis is significant and perhaps more prevalent than with other commercially available valves 24,25,30,31 …”

Section: Discussionmentioning

confidence: 99%

“…The patients were assessed 1 day after the procedure and in the out- Although a definitive study is still not available, circumstantial and retrospective cohort data suggests that the incidence of infective endocarditis is significant and perhaps more prevalent than with other commercially available valves. 24,25,30,31 The introduction of the straight Venus P-valve™ onto the market in Europe, Asia and perhaps in the US in the future will pro- Fluoroscopy time (min) 33.7 ± 7.9…”

Section: Follow Upmentioning

confidence: 99%

“…As our minds have been appropriately focused on these strategies, the global uptake and confidence in the Melody™ valve (Medtronic, Minneapolis, MN) for smaller stenotic outflows has been sustained. No other valve has come to the market, which matches its profile of indications 22–24 . Whilst the Melody™ valve has defined the recent era of innovation in congenital intervention, it naturally has limitations in both its design and materials 25–27 .…”

Section: Introductionmentioning

confidence: 99%

“…No other valve has come to the market, which matches its profile of indications. [22][23][24] Whilst the Melody™ valve has defined the recent era of innovation in congenital intervention, it naturally has limitations in both its design and materials. [25][26][27] The straight design Venus P-valve™ (Venus MedTech, Hangzhou, China) may provide an alternative to the Melody™ valve in smaller, or stenosed right ventricular outflow tracts (RVOTs).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Early clinical experience with the straight design of Venus P‐valve™ in dysfunctional right ventricular outflow tracts

Morgan

Sivakumar

Promphan

et al. 2020

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

Objectives: To assess the initial procedural and short to medium-term experience with the straight design of the Venus P-valve™ (Venus MedTech, Hangzhou, China) in dysfunctional right ventricular outflow tracts (RVOT). Background: The Melody™ valve (Medtronic, Minneapolis, Minnesota) has been the only percutaneous valve option for smaller RVOT conduits. The straight Venus P-valve™ may provide an alternative to the Melody™ valve. Methods: Retrospective data collection of patient characteristics, procedural data, clinical and imaging follow-up of the straight Venus P-valve™. Results: Nine patients (four female) with a mean age of 23.1 ± 7.5 years and a mean weight of 72.7 ± 29.4 kg underwent straight Venus P-valve™ implantation between 03/2014 and 06/2016. All patients had right ventricle-to-pulmonary artery conduits which were pre-stented before the valve implantation. All valves were deployed successfully without any significant procedural complications. During the mean followup of 24 ± 9.1 months, there were no valve related re-interventions or deterioration in valve performance. There was one case of insignificant, single wire frame fracture and no cases of endocarditis. The cohort demonstrated a reduction in pulmonary regurgitation and tricuspid regurgitation, which was sustained throughout the followup. Similarly the gradient across the RVOT tract did not significantly increase. Conclusions: Implantation of the straight Venus P-valve™ has provided satisfactory short to mid-term results with high success rates and no complications and may be considered as an alternative option in patients with RVOT dysfunction. K E Y W O R D S congenital heart disease, percutaneous intervention, transcatheter pulmonary valve 1 | INTRODUCTION Developments in percutaneous pulmonary valve technology have expanded rapidly in the last 10 years. 1-8 The most recent focus has been on the major area of unmet need, the large regurgitant "native" outflow tract. 9-16 This expansion has combined the development of innovative techniques to apply currently available

show abstract

Current Treatment Options for Catheter-Based Pulmonary Valve Replacement in Children

Zablah

Morgan

2020

Curr Treat Options Peds

View full text Add to dashboard Cite

Pulmonary Regurgitation- Is the Future Percutaneous or Surgical?

Cited by 7 publications

References 33 publications

A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data†

A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data†

Early clinical experience with the straight design of Venus P‐valve™ in dysfunctional right ventricular outflow tracts

Current Treatment Options for Catheter-Based Pulmonary Valve Replacement in Children

Contact Info

Product

Resources

About